Muutke küpsiste eelistusi

Medullary Thyroid Carcinoma: Biology, management, and treatment of sporadic and hereditary MTC Second Edition 2025 [Kõva köide]

Edited by , Edited by
  • Formaat: Hardback, 307 pages, kõrgus x laius: 235x155 mm, 30 Illustrations, color; 18 Illustrations, black and white; XVI, 307 p. 48 illus., 30 illus. in color., 1 Hardback
  • Sari: Recent Results in Cancer Research 223
  • Ilmumisaeg: 20-Mar-2025
  • Kirjastus: Springer International Publishing AG
  • ISBN-10: 3031803957
  • ISBN-13: 9783031803956
Teised raamatud teemal:
  • Kõva köide
  • Hind: 132,08 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Tavahind: 155,39 €
  • Säästad 15%
  • Raamatu kohalejõudmiseks kirjastusest kulub orienteeruvalt 2-4 nädalat
  • Kogus:
  • Lisa ostukorvi
  • Tasuta tarne
  • Tellimisaeg 2-4 nädalat
  • Lisa soovinimekirja
  • Formaat: Hardback, 307 pages, kõrgus x laius: 235x155 mm, 30 Illustrations, color; 18 Illustrations, black and white; XVI, 307 p. 48 illus., 30 illus. in color., 1 Hardback
  • Sari: Recent Results in Cancer Research 223
  • Ilmumisaeg: 20-Mar-2025
  • Kirjastus: Springer International Publishing AG
  • ISBN-10: 3031803957
  • ISBN-13: 9783031803956
Teised raamatud teemal:
After 10 years, this second edition is extensively rewritten and updated and provides a source of information concerning all aspects of medullary thyroid carcinoma, including comprehensive actual references for interested scientists.



Medullary thyroid carcinoma (MTC) is a rare unique tumor which differs from other thyroid tumors by originating from the neuroendocrine C-cell, secreting the specific tumor marker calcitonin. MTC is associated in about 25% of cases with multiple endocrine neoplasia type 2, an autosomal dominant familial disorder causing tumors within various endocrine glands. The molecular genetics of tumor development is clarified: hereditary as well as sporadic MTC are linked to mutations in the RET proto- oncogene coding for a tyrosine kinase. These RET mutations serve as a genetic marker for hereditary MTC and allow for prophylactic thyroidectomy in gene carriers. The RET-tyrosine kinase is also a new therapeutic target using selective  tyrosine kinase inhibitors improving the outcome of advanced metastasized MTC. 



This book will be an ideal source of up-to-date information for a wide range of practitioners, including endocrinologists, oncologists, internal medicine specialists, geneticists, and nuclear medicine physicians.
What is new?.- Thyroid C-Cell Biology and Oncogenic Transformation.-
Histopathology of C cells and medullary thyroid carcinoma.- Epidemiology and
clinical presentation of Medullary Thyroid Carcinoma.- Medullary thyroid
carcinoma: Imaging.- Calcitonin as a Biomarker for Medullary Thyroid
Carcinoma.- Hereditary Medullary Thyroid Cancer, Genotype phenotype
correlation.- Pheochromocytomas in Multiple Endocrine Neoplasia type 2.-
Primary hyperparathyroidism in Multiple Endocrine Neoplasia 2 Syndrome.-
Surgical treatment of  medullary thyroid carcinoma.- Long term follow up in
medullary thyroid carcinoma.- Use of Tyrosine Kinase Inhibitors for Treatment
of Medullary Thyroid Carcinoma.